Full-Time

Test Architect

HeartFlow

HeartFlow

501-1,000 employees

Non-invasive cardiac imaging to guide treatment

Compensation Overview

$190k - $250k/yr

+ Bonus + Equity

San Francisco, CA, USA

In Person

Bachelor's

Category
QA & Testing (1)
Required Skills
Python
JavaScript
Software Testing
Postman
Java
TypeScript
AWS
Playwright
C/C++
Selenium

Get referred to HeartFlow

See people who can refer or advise you

Requirements
  • 8–12 years of experience in software test engineering, SDET, or quality engineering roles, with a strong record as a hands-on technical leader who has personally architected automation frameworks.
  • Substantial experience testing Software as a Medical Device (SaMD) or other regulated medical device software, including ownership of test strategy on shipped products.
  • Deep working knowledge of medical device Quality Management System practices and applicable standards (e.g., ISO 13485, IEC 62304, ISO 14971, 21 CFR Part 820), including test documentation, traceability, tool validation, and audit support.
  • Expert-level proficiency with Selenium / WebDriver and Playwright, including framework architecture, large-scale stability and flake reduction, and parallel execution at scale.
  • Track record designing, scaling, and maintaining End-to-End automation frameworks covering complete workflows and complex system integrations.
  • Experience setting test plan, protocol, and report standards in a regulated environment, with rigorous traceability across requirements, test cases, and evidence.
  • Demonstrated leadership in adopting AI-assisted testing tools and techniques (e.g., AI-augmented authoring, self-healing automation, LLM-driven test generation or triage).
  • Strong programming skills in at least one mainstream language used for automation (e.g., Python, TypeScript/JavaScript, Java, or C#); able to set coding standards for the test organization.
  • Deep experience with API and contract testing approaches (REST Assured, Postman, Karate, Pact, or equivalent).
  • Strong experience integrating automated tests into CI/CD pipelines and working with cloud environments such as AWS.
  • Excellent analytical and debugging skills across distributed systems; able to participate in root-cause investigations on the most complex failures.
  • Excellent written and verbal communication skills; able to influence engineers, leaders, and cross-functional partners.
  • Bachelor's degree in Computer Science, Engineering, or a related field, or equivalent practical experience.
Responsibilities
  • Set and evolve the technical strategy for end-to-end (E2E) test automation across Heartflow's full pipeline, defining patterns, frameworks, and architecture that scale with the platform.
  • Drive the AI-first approach to test automation: define how AI-assisted authoring, self-healing locators, AI generated spec driven test development and LLM-driven triage are adopted, evaluated, and rolled out across teams.
  • Architect and own post-deployment testing capabilities, including production smoke, synthetic monitoring, and continuous validation against live environments.
  • Design test depth and rigor calibrated to each software component's safety classification, ensuring higher-risk components receive deeper verification and evidence.
  • Author the most complex and consequential test plans, protocols, and reports; set the standards and templates other engineers follow under our QMS.
  • Lead tool validation strategy for test infrastructure and automation tooling, partnering with RA/QA to ensure validation evidence meets regulatory expectations.
  • Architect, build, and continually improve UI and mobile automation including but not limited to Selenium and Playwright — driving stability, parallelism, observability, and reuse across products, including our WebGL-based 3D viewer and desktop clinical applications.
  • Define API and integration testing standards using tools such as REST Assured, Postman, Karate, and contract testing where appropriate.
  • Define testing standards for medical imaging and clinical data interoperability protocols, and for report/document output validation.
  • Partner with engineering, product, and RA/QA leaders to translate complex requirements into verifiable test strategies with full traceability.
  • Own the technical relationship between requirements management and traceability tooling, ensuring every automated test maps to a documented requirement and audit-ready evidence.
  • Lead deep root-cause investigations on the highest-impact issues across distributed systems and drive systemic prevention of recurrence.
  • Define how automated tests are integrated into CI/CD to deliver fast, reliable, actionable feedback to engineering teams.
  • Serve as a primary technical owner for quality-related audits, CAPAs, and regulatory submissions, providing test evidence, traceability, and documentation.
  • Mentor senior and mid-level engineers; lead technical reviews, raise the bar on quality engineering practices, and grow the team's technical depth.
  • Help define hiring profiles and lead technical interviews for future Test Engineering hires and contractor partners.
  • Influence cross-functional decisions on quality strategy, tooling investments, and engineering process improvements.
Desired Qualifications
  • Direct experience with requirements/traceability tooling such as Ketryx, Jama, or Polarion.
  • Experience with DICOM and/or HL7 protocols, or other clinical data interoperability standards.
  • Experience leading RA/QA partnerships during regulatory audits and inspections.
  • Experience defining test strategy for ML/AI systems, clinical validation workflows, or medical imaging products.
  • Experience validating complex visualizations (qualitative and quantitative) such as 3D models, overlays, and measurement views.
  • Experience automating legacy desktop applications (e.g., Windows/C++) using tools such as WinAppDriver.
  • Experience designing and managing diverse test datasets (synthetic, anonymized, adversarial).
  • Experience defining non-functional / performance testing strategy with tools such as k6, Locust, JMeter, or Gatling.
  • Experience with data-pipeline testing and microservices architectures at scale.
  • Demonstrated ability to define, own, and evolve actionable quality metrics.

HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2010

Get referred to HeartFlow

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $64.1 million, up 48%, and guidance rose.
  • Plaque Analysis generated $7.8 million in Q2 2026 and gained strong reimbursement.
  • Heartflow plans Q4 2026 trials targeting asymptomatic patients and a $11 billion TAM.

What critics are saying

  • Heartflow sued Cleerly in April 2026, signaling a costly IP war in cardiac AI.
  • Plaque revenue still depends on new account activation and physician workflow adoption.
  • CMS reimbursement changes after 2026 could crush growth and weaken Heartflow’s platform economics.

What makes HeartFlow unique

  • Heartflow One combines FFRCT, Plaque Analysis, and Plaque Staging in one workflow.
  • July 2026 SCCT data covered 36,000 patients and 16 years of follow-up.
  • Heartflow’s FDA-cleared plaque product carries Medicare and major commercial payer coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 20th, 2026
HeartFlow CMO sells $380K in shares as stock surges 35% in one year

HeartFlow's Chief Medical Officer Campbell Rogers sold 9,219 shares on 17 August 2026 for approximately $380,100, according to an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan adopted in December 2025. Rogers retains a significant stake in the company, holding 86,459 shares directly and 145,540 shares indirectly through various trusts, representing a 0.27% ownership. He also maintains 82,972 options vesting monthly through August 2029. HeartFlow's shares closed at $45.23 on 18 August 2026, achieving a 35% one-year return as of the transaction date. The company, which develops AI-powered cardiac diagnostic solutions, has a market capitalisation of $3.9 billion with trailing twelve-month revenue of $212.1 million and a net loss of $118.4 million.

Yahoo Finance
Aug 18th, 2026
HeartFlow raises 2026 guidance to $246M–$250M revenue on 48% Q2 growth

Heartflow reported second quarter 2026 revenue of $64.1 million, up 48% year-over-year, driven by increased US case volumes for its FFRCT and Plaque products. The AI-powered coronary artery disease diagnostics company posted a gross margin of 83.0% and a net operating loss of $17.9 million. The company raised its full-year revenue guidance to $246 million to $250 million, representing approximately 40% to 42% growth, up from previous guidance of $228 million to $232 million. It also increased its non-GAAP gross margin outlook to approximately 82% from 81%. CEO John Farquhar said the Plaque product is emerging as a "meaningful second growth engine" alongside the core FFRCT business, helping win new accounts and deepen physician utilisation.

Yahoo Finance
Aug 14th, 2026
HeartFlow revenue surges 48% to $64.1M as plaque product drives record growth

HeartFlow reported second quarter 2026 revenue of $64.1 million, up 48% year over year. US revenue grew 51% to $59.6 million, marking the company's fastest growth in eight quarters. The medical technology firm's Plaque product generated $7.8 million in revenue, exceeding expectations. Total global revenue cases reached 84,491, up 74% year over year. Gross margin expanded to 83.3% from 75.6% in the prior year period, driven by AI efficiencies and higher-margin Plaque mix. HeartFlow raised its full-year 2026 revenue guidance to $246 million to $250 million, representing 40% to 42% growth. The company also increased its Plaque revenue outlook to $29 million to $31 million. The non-GAAP operating loss narrowed to $7.9 million from $11.5 million last year. HeartFlow ended the quarter with $246.8 million in cash and investments.

MarketBeat
Aug 14th, 2026
Heartflow (NASDAQ:HTFL) shares gap up following better-than-expected earnings.

Heartflow (NASDAQ:HTFL) shares gap up following better-than-expected earnings. August 14, 2026 Key points. * Heartflow shares surged after the company reported adjusted EPS of $(0.07), beating estimates of $(0.22), while quarterly revenue reached $64.08 million, up 47.7% year over year. * The stock opened at $39.06 versus a prior close of $31.01 and last traded near $41.07, above the analyst consensus target of $38.86. * Analysts maintain a generally positive outlook, with MarketBeat reporting a "Moderate Buy" consensus, although insiders have sold 115,805 shares worth approximately $3.53 million over the past three months. * Interested in Heartflow? Here are five stocks we like better. Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) shares gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $31.01, but opened at $39.06. Heartflow shares last traded at $41.0730, with a volume of 1,793,589 shares changing hands. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. The company's revenue for the quarter was up 47.7% on a year-over-year basis. Wall Street analyst weigh in. A number of research firms have recently commented on HTFL. Piper Sandler reissued an "overweight" rating on shares of Heartflow in a research note on Friday. Canaccord Genuity Group decreased their target price on Heartflow from $43.00 to $37.00 and set a "buy" rating for the company in a research note on Friday, May 15th. Freedom Capital upgraded shares of Heartflow to a "strong-buy" rating in a research report on Tuesday, June 30th. William Blair started coverage on shares of Heartflow in a report on Monday, May 4th. They issued an "outperform" rating for the company. Finally, Weiss Ratings raised shares of Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Heartflow presently has an average rating of "Moderate Buy" and an average target price of $38.86. Insider buying and selling at Heartflow. In other news, CEO John C.M. Farquhar sold 22,562 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $28.31, for a total transaction of $638,730.22. Following the completion of the sale, the chief executive officer directly owned 436,280 shares of the company's stock, valued at $12,351,086.80. This represents a 4.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares of the company's stock, valued at $2,231,236.54. This trade represents a 10.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 115,805 shares of company stock valued at $3,530,609. Corporate insiders own 7.70% of the company's stock. Institutional trading of Heartflow. A number of hedge funds have recently bought and sold shares of HTFL. TrueMark Investments LLC raised its holdings in shares of Heartflow by 1.4% during the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company's stock valued at $654,000 after acquiring an additional 379 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow during the 4th quarter worth approximately $27,000. Strs Ohio grew its position in Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company's stock worth $112,000 after purchasing an additional 1,200 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Heartflow during the 4th quarter valued at $45,000. Finally, Legal & General Group Plc purchased a new stake in shares of Heartflow in the third quarter valued at $59,000. Heartflow price performance. The company has a market cap of $3.52 billion and a PE ratio of -13.18. The stock has a fifty day moving average price of $28.80 and a 200-day moving average price of $27.70. Heartflow company profile. HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements. HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Heartflow, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list. While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

MarketBeat
Aug 1st, 2026
Heartflow (NASDAQ:HTFL) stock rating upgraded by Robert W. Baird.

Heartflow (NASDAQ:HTFL) stock rating upgraded by Robert W. Baird. August 1, 2026 Key points. * Robert W. Baird upgraded Heartflow to "strong buy," joining another strong-buy recommendation. Analysts' overall consensus is "Moderate Buy," with an average price target of $36.57. * Heartflow opened at $25.23, down 2.3%, with a $2.18 billion market capitalization. Its latest quarterly results beat EPS expectations, while revenue increased 41.3% year over year to $52.59 million. * Company insiders sold 115,805 shares worth approximately $3.55 million in the last quarter, while several institutional investors - including Vanguard and Franklin Resources - recently established positions. * Five stocks to consider instead of Heartflow. Heartflow (NASDAQ:HTFL - Get Free Report) was upgraded by equities research analysts at Robert W. Baird to a "strong-buy" rating in a research note issued to investors on Friday,Zacks.com reports. HTFL has been the subject of several other reports. Stifel Nicolaus set a $40.00 target price on Heartflow in a research note on Wednesday, July 15th. Piper Sandler reaffirmed an "overweight" rating on shares of Heartflow in a report on Thursday, June 11th. Weiss Ratings lowered Heartflow from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, July 8th. Wells Fargo & Company lifted their price objective on shares of Heartflow from $35.00 to $37.00 and gave the company an "overweight" rating in a research report on Friday, May 15th. Finally, Freedom Capital raised Heartflow to a "strong-buy" rating in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.57. Heartflow trading down 2.3%. NASDAQ HTFL opened at $25.23 on Friday. Heartflow has a 12-month low of $20.13 and a 12-month high of $41.22. The company has a fifty day simple moving average of $29.02 and a two-hundred day simple moving average of $28.10. The stock has a market cap of $2.18 billion and a P/E ratio of -8.11. Heartflow (NASDAQ:HTFL - Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million for the quarter. The business's revenue was up 41.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Heartflow will post -0.82 earnings per share for the current year. Insider buying and selling at Heartflow. In other news, insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the transaction, the insider owned 78,731 shares in the company, valued at approximately $2,231,236.54. This trade represents a 10.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the sale, the chief executive officer directly owned 457,935 shares of the company's stock, valued at approximately $16,027,725. This trade represents a 7.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,805 shares of company stock worth $3,548,884 in the last quarter. Company insiders own 7.70% of the company's stock. Institutional investors weigh in on Heartflow. Institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. purchased a new stake in Heartflow during the third quarter worth about $48,871,000. Legal & General Group Plc acquired a new position in shares of Heartflow in the third quarter worth $59,000. Franklin Resources Inc. acquired a new stake in shares of Heartflow in the third quarter valued at $10,829,000. UBS Group AG acquired a new position in Heartflow during the 3rd quarter worth $5,130,000. Finally, Sei Investments Co. purchased a new position in shares of Heartflow in the 3rd quarter valued at about $303,000. About Heartflow. HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements. HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Heartflow, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list. While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.